Sugi Predict

Sugi Predict / Compounds / SCHEMBL1928396

SCHEMBL1928396

SCHEMBL1928396

CC(C)(C)OC(=O)N1CCN(c2ccccc2Br)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GPR119 Q8TDV5 2/20 0.52
▸ ALDH1A1 P00352 1/20 0.51
▸ LMNA P02545 1/20 0.51
▸ MAPT P10636 1/20 0.51
▸ CKS1B P61024 2/20 0.51
▸ SKP1 P63208 2/20 0.51
▸ SKP2 Q13309 2/20 0.51
▸ SMARCA2 P51531 1/20 0.51
▸ SMARCA4 P51532 1/20 0.51
▸ PBRM1 Q86U86 1/20 0.51
▸ BACE1 P56817 2/20 0.50
▸ NAMPT P43490 1/20 0.50
▸ POLB P06746 1/20 0.49
▸ MEN1 O00255 1/20 0.49
▸ KMT2A Q03164 1/20 0.49
▸ GAA P10253 1/20 0.49
▸ SMN1; SMN2 Q16637 1/20 0.49
▸ CHRM2 P08172 1/20 0.48
▸ CHRM4 P08173 1/20 0.48
▸ CHRM1 P11229 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30062550 1.00 GPR119 (0.52) GPR119ALDH1A1LMNAMAPTCKS1B
SCHEMBL16597110 0.87 MAPT (0.54) GPR119ALDH1A1LMNAMAPTCKS1B
SCHEMBL6634016 0.86 SMARCA2 (0.50) GPR119ALDH1A1LMNAMAPTCKS1B
SCHEMBL26112771 0.86 ALDH1A1 (0.47) GPR119ALDH1A1LMNAMAPTCKS1B
SCHEMBL17276765 0.85 CKS1B (0.55) GPR119ALDH1A1LMNAMAPTCKS1B
SCHEMBL223688 0.84 POLB (0.61) GPR119ALDH1A1LMNAMAPTPOLB
SCHEMBL27099087 0.84 BACE1 (0.45) GPR119ALDH1A1LMNAMAPTCKS1B
SCHEMBL30613376 0.84 GAA (0.69) GPR119ALDH1A1LMNAMAPTCKS1B
SCHEMBL3436307 0.84 AKR1C3 (0.57) GPR119ALDH1A1LMNAMAPTCKS1B
SCHEMBL30208139 0.84 MEN1 (0.56) GPR119ALDH1A1LMNAMAPTCKS1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104829558-B Preparation method of diaryl thioether amine compound 江苏豪森药业集团有限公司 2020-03-03 — — CN claimed
CN-110105308-A Preparation method of vortioxetine 山东京卫制药有限公司 2019-08-09 — — CN claimed
US-12435078-B2 Pyridazinones and methods of use thereof GFB (ABC), LLC (US) 2025-10-07 — — US disclosed
CN-118221612-A Preparation method of l- [2- (2, 4-dimethylbenzenesulfide) -phenyl ] piperazine halogen acid salt 浙江华海药业股份有限公司 2024-06-21 — — CN disclosed
CN-117050035-B Preparation method of hydrobromic acid voltammetric acid duloxetine 山东锐顺药业有限公司 2024-04-02 — — CN disclosed
CN-117050035-A Preparation method of hydrobromic acid voltammetric acid duloxetine 山东锐顺药业有限公司 2023-11-14 — — CN disclosed
US-20230203028-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GFB (ABC), LLC 2023-06-29 — — US disclosed
US-20230203028-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GFB (ABC), LLC 2023-06-29 — — US disclosed
US-20230203028-A1 PYRIDAZINONES AND METHODS OF USE THEREOF GFB (ABC), LLC 2023-06-29 — — US disclosed
CN-109912514-B (2-heteroarylaminophenyl) nitrogen heterocyclic derivative and application thereof 广东东阳光药业有限公司 2022-11-18 — — CN disclosed
US-11261164-B2 Small molecule agonists of neurotensin receptor 1 Sanford Burnham Prebys Medical Discovery Institute (US) 2022-03-01 — — US disclosed
US-7125896-B2 Thiophene carboxamide compounds as inhibitors of enzyme IKK-2 ASTRAZENECA AB (SE) 2006-10-24 — — US disclosed
CN-1263751-C Novel compounds ASTRAZENECA AB (SE) 2006-07-12 — — CN disclosed
EP-1592772-A2 5HT7 ANTAGONISTS AND INVERSE AGONISTS Pfizer Products Incorporated (US) 2005-11-09 — — EP disclosed
US-20040242573-A1 Novel compounds ASTRAZENECA AB (SE) 2004-12-02 — — US disclosed
US-20040229874-A1 5HT7 Antagonists and inverse agonists PFIZER INC. 2004-11-18 — — US disclosed
CN-1541214-A Novel compounds — 2004-10-27 — — CN disclosed
WO-2004067703-A2 5HT7 ANTAGONISTS AND INVERSE AGONISTS PFIZER PRODUCTS INC. (US) 2004-08-12 — — WO disclosed
EP-1421074-A1 NOVEL COMPOUNDS AstraZeneca AB (SE) 2004-05-26 — — EP disclosed
WO-2003010158-A1 NOVEL COMPOUNDS ASTRAZENECA AB (SE) 2003-02-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230203028-A1 PYRIDAZINONES AND METHODS OF USE THEREOF PDXK, ATP6V1B1, REN GPR119 846/4885ALDH1A1 649/4885LMNA 715/4885
US-11261164-B2 Small molecule agonists of neurotensin receptor 1 NTSR1, NTSR2, VIPR1 GPR119 50/4885ALDH1A1 3294/4885LMNA 3727/4885
US-20040242573-A1 Novel compounds SULT1E1, TPMT, UGT1A1 GPR119 92/4885ALDH1A1 52/4885LMNA 3431/4885
US-12435078-B2 Pyridazinones and methods of use thereof PDXK, ATP6V1B1, REN GPR119 846/4885ALDH1A1 649/4885LMNA 715/4885
US-20040229874-A1 5HT7 Antagonists and inverse agonists HTR7, HTR1A, HTR1B GPR119 133/4885ALDH1A1 1099/4885LMNA 3490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.